Anti-EGFR Antibody [SP00-86]

HUABIO

Anti-EGFR Antibody [SP00-86]

7

Flow Cytometry, ImmunoFluorescence, ImmunoPrecipitation, Western Blot

WB,IF-Cell,IF-Tissue,IHC-P,IP,FC

Research Use Only

Monoclonal

SP00-86

1 mg/ml

Unconjugated

EGFR

epidermal growth factor receptor

ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS, PIG61, mENA, epidermal growth factor receptor, EGFR vIII, avian erythroblastic leukemia viral (v-erb-b) oncogene homolog, cell growth inhibiting protein 40, cell proliferation-inducing protein 61, epidermal growth factor receptor tyrosine kinase domain, erb-b2 receptor tyrosine kinase 1, proto-oncogene c-ErbB-1, receptor tyrosine-protein kinase erbB-1

Rabbit

IgG

Epidermal growth factor receptor

The EGF receptor family comprises several related receptor tyrosine kinases that are frequently overexpressed in a variety of carcinomas. Members of this receptor family include EGFR (HER1), Neu (ErbB-2, HER2), ErbB-3 (HER3) and ErbB-4 (HER4), which form either homodimers or heterodimers upon ligand binding. Exons in the EGFR gene product are frequently either deleted or duplicated to produce deletion mutants (DM) or tandem duplication mutants (TDM), respectively, which are detected at various molecular weights. EGFR binds several ligands, including epidermal growth factor (EGF), transforming growth factor alpha (TGFalpha), Amphiregulin and heparin binding-EGF (HB-EGF). Ligand binding promotes the internalization of EGFR via Clathrin-coated pits and its subsequent degradation in response to its intrinsic tyrosine kinase. EGFR is involved in organ morphogenesis and maintenance and repair of tissues, but upregulation of EGFR is associated with tumor progression. The oncogenic effects of EGFR include initiation of DNA synthesis, enhanced cell growth, invasion and metastasis. Abrogation of EGFR results in cell cycle arrest, apoptosis or dedifferentiation of cancer cells, suggesting that EGFR may be an effective therapeutic target.

Human, Mouse

Human,Mouse

Rat

-20°C,2°C to 8°C

41116161